AbbVie aims for FDA filing on first hep C drug in 2014's second quarter

With Gilead's ($GILD) pioneering hepatitis C drug sofosbuvir moving closer to a likely approval and a megablockbuster market, AbbVie ($ABBV) is looming from behind with some promising results from the first of 6 Phase III studies of its breakthrough triple-threat therapy. And AbbVie is vowing today that the successful late-stage effort sets the stage for a regulatory filing in the second quarter of 2014. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.